Regeneron Pharmaceuticals has entered a new manufacturing and supply agreement with Fujifilm Diosynth Biotechnologies to ...

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

We are excited about this unique relationship, and we are already working to bring capacity online at Fujifilm’s biologics manufacturing facility in Holly Springs, North Carolina.” ...

“When you think about a pharmaceutical company, they’re entrusting somebody to be able to make their babies for them,” Laurie Braxton, head of North Carolina operations at Fujifilm Diosynth ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Hathway’s technology uses natural epigenetic processes to dial gene activity up or down, rather than rewriting the genetic ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...